The new method can significantly inhibit the metastasis of breast cancer

April 18, 2019 / BIOON / - breast cancer cells are like a house with three locks at the front door Keys, or receptors, allow drugs to open doors and kill cells However, these key factors do not exist in triple negative breast cancer So far, few breast cancer drugs are available A protein called p53 suppresses and kills cancer in the body However, p53 with defective mutation can promote the growth and reproduction of cancer cells Photo source: researchers at the University of Missouri at http://cn.bing.com now find that combination therapy can reduce the risk of triple negative breast cancer spreading to other parts of the body by 50% "Most patients who die of breast cancer (especially triple negative breast cancer) are due to cancer metastasis "Said Salman Hyder, Professor of tumor neovascularization and professor of biomedical science at the school of veterinary medicine and Dalton cardiovascular disease research center "At present, we lack chemotherapy for triple negative breast cancer Therefore, people take toxic non-specific drugs We want to see if this combination therapy can provide a new non-toxic treatment The study was based on previous studies in Hyder's laboratory, using mice with human metastatic cancer that had spread to the lungs The researchers wanted to see if two drugs previously found - apr-246, which restores the ability of p53 to kill cancer cells, and 2ag4, which targets blood vessels to kill cancer cells - had an impact on metastatic triple negative breast cancer Hyder said the results were promising "When the two compounds are used alone, the number of cancer metastasis nodules decreases, and when the two compounds are used together, the number of cancer metastasis nodules decreases increases," Hyder said More importantly, if the two drugs were used together, the number of mice with breast cancer would be reduced by 50% " Both apr-246 and 2ag4 are currently undergoing human clinical trials The researchers hope that these findings can enhance the personalized treatment of breast cancer by reducing existing cancer cells and preventing cancer from spreading to other parts of the body The study highlights the power of transforming precision medicine and the future of the program proposed by mu The program will bring together industry partners, schools and colleges on campus, as well as federal and state governments to make accurate and personalized healthcare possible Mu's scientific progress will be effectively transformed into new drugs, equipment and treatment means, providing personalized patient care according to individual genes, environment and lifestyle, and ultimately improving people's health and well-being Hyder presented the study at the 2019 annual meeting of the endocrine society in New Orleans, entitled "targeting mutant p53 alone or in combination with a photodynamic Serie specific antibodie suppresses growth and metabolism of human breast cancer: a strategy towards enhancing personalized medicine." Reference: preventing triple negative breast cancer from spreading